Physician profile
Pamela Blake
NPI 1548268691
$12,274.92
in general payments reported to CMS, 2019-2025
24 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $424 · 2021: $830 · 2022: $781 · 2023: $6,842 · 2024: $1,373 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,725 · Food and Beverage: $3,560 · Travel and Lodging: $953 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,725.00 |
| Food and Beverage | $3,559.99 |
| Travel and Lodging | $953.12 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,942.21 | 2021-2025 | Botox, Qulipta |
| Teva Pharmaceuticals USA, INC. | $957.96 | 2019-2024 | Ajovy |
| Tonix Medicines, INC. | $536.03 | 2024-2025 | Zembrace Symtouch |
| Lilly USA, LLC | $517.27 | 2019-2024 | Emgality |
| Amgen INC. | $361.30 | 2019-2023 | Aimovig |
| Lundbeck LLC | $329.67 | 2021-2025 | Vyepti |
| Allergan, INC. | $316.46 | 2019-2022 | |
| Pfizer INC. | $250.22 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $186.98 | 2025 | Dysport |
| Biohaven Pharmaceuticals, INC. | $139.09 | 2021 | |
| Upsher-Smith Laboratories LLC | $113.94 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $98.25 | 2022 | |
| Merz Pharmaceuticals, LLC | $79.59 | 2025 | Xeomin |
| Impel Pharmaceuticals LLC | $68.11 | 2024-2025 | Trudhesa |
| Axsome Therapeutics, INC. | $67.13 | 2025 | Symbravo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $53.98 | 2023-2024 | Ztlido |
| Janssen Pharmaceuticals, INC | $53.56 | 2024-2025 | Spravato |
| Kowa Pharmaceuticals America, INC. | $46.94 | 2022-2023 | Seglentis |
| Supernus Pharmaceuticals, INC. | $44.93 | 2023-2024 | Qelbree, Qelbree |
| Boston Scientific Corporation | $33.88 | 2022-2025 | Watchman Flx |
| Amneal Pharmaceuticals LLC | $27.37 | 2019 | |
| Currax Pharmaceuticals LLC | $19.54 | 2020 | |
| Assertio Therapeutics, INC. | $16.20 | 2020 | |
| Impel Pharmaceuticals INC. | $14.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.